This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Q3 Earnings Season Preview
by Sheraz Mian
All the big banks are on this week's reporting docket
Crash-Proof Stocks To Buy Now
by Brian Bolan
Crashes happen, but not all stocks are treated the same during the crash.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
Banks in Focus as Q2 Earnings Season Ramps Up
by Sheraz Mian
Banks had an overall decent time in Q2.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
The Republican- led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
The Republican-led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
The Republican-led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss
by Zacks Equity Research
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
A Good Start to Q2 Earnings Season
by Sheraz Mian
The 2014 Q2 earnings season has gotten off to a relatively positive start.